Under the terms of the deal, Gilead will put down $120 million in an upfront payment and will promise up to $1.52 billion in ...
CMS Administrator Mehmet Oz clarified that a deal has not yet been sealed with the manufacturer of semaglutide, Novo Nordisk, ...
The Commissioner’s National Priority Voucher awards companies that align with specific national priorities—such as boosting ...
EMD Serono will offer its fertility treatments on TrumpRx at a steep discount, and Roche’s direct-to-consumer offering will ...
Biopharma professionals aren’t typically hired right away, based on a BioSpace LinkedIn poll. In the past year, only about ...
Veradermics is the second hair regrowth specialist to fundraise this week, after Pelage Pharmaceuticals announced Wednesday ...
An unnamed source clarified that Sandra Retzky has not been fired from the FDA, but it remains unclear where she was ...
The company is pursuing a Phase III trial for its topical stem cell-rejuvenating molecule that aims to reactivate hair growth ...
Kailera’s lead asset, KAI-9531, elicited an average weight loss of more than 17% in a Phase III study in China. The biotech ...
Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene ...
Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s ...
Due largely to CSL, Merck and Novo Nordisk’s reorganizations that could total about 19,350 people, Q3 cuts rose significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback